These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32660171)

  • 1. [Advances in the study of cellular immunotherapy for liver cancer].
    Su S; Huang XW
    Zhonghua Gan Zang Bing Za Zhi; 2020 Jun; 28(6):461-465. PubMed ID: 32660171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Progress in immunotherapy for hepatocellular carcinoma].
    Shen Z; Li M; Bai S; Yang Q; Zhang F; Tang M; Guo J; Yang Z
    Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2326-2338. PubMed ID: 31880139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research progress of immunotherapy alone and in combination for liver cancer].
    Wu ZJL; Li K; Zhang K; Gong WD
    Zhonghua Gan Zang Bing Za Zhi; 2020 Jun; 28(6):471-474. PubMed ID: 32660173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
    Mukaida N; Nakamoto Y
    World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive cell transfer therapy for hepatocellular carcinoma.
    Zhang R; Zhang Z; Liu Z; Wei D; Wu X; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):3-11. PubMed ID: 30659408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune cell therapy for hepatocellular carcinoma.
    Mizukoshi E; Kaneko S
    J Hematol Oncol; 2019 May; 12(1):52. PubMed ID: 31142330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revolutionizing gastric cancer treatment: The potential of immunotherapy.
    Christodoulidis G; Koumarelas KE; Kouliou MN
    World J Gastroenterol; 2024 Jan; 30(4):286-289. PubMed ID: 38313231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research progress and clinical prospect of immunocytotherapy for the treatment of hepatocellular carcinoma.
    Shi Y; Men X; Li X; Yang Z; Wen H
    Int Immunopharmacol; 2020 Mar; 82():106351. PubMed ID: 32143005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer.
    Yan W; Hu H; Tang B
    Onco Targets Ther; 2019; 12():8015-8022. PubMed ID: 31686857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current status and treatment strategies for liver injury before targeted immunotherapy for liver cancer].
    Jia JM; Ren JS; Zhang LY
    Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1133-1136. PubMed ID: 38238945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T Cell-Associated Immunotherapy for Hepatocellular Carcinoma.
    Ma W; Wu L; Zhou F; Hong Z; Yuan Y; Liu Z
    Cell Physiol Biochem; 2017; 41(2):609-622. PubMed ID: 28214839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Function of tumor infiltrating lymphocytes in solid tumors - a review].
    Bai S; Yang X; Zhang N; Zhang F; Shen Z; Yang N; Zhang W; Yu C; Yang Z
    Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2308-2325. PubMed ID: 31880138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.
    Li K; Lan Y; Wang J; Liu L
    Tumour Biol; 2017 Mar; 39(3):1010428317692229. PubMed ID: 28347250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.
    Weller M; Fontana A
    Brain Res Brain Res Rev; 1995 Sep; 21(2):128-51. PubMed ID: 8866671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy.
    Jiang Y; Han QJ; Zhang J
    World J Gastroenterol; 2019 Jul; 25(25):3151-3167. PubMed ID: 31333308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Liver cancer immunotherapy in the context of precision medicine].
    Huan HB; Chen XJ; Xia F
    Zhonghua Gan Zang Bing Za Zhi; 2020 Nov; 28(11):910-914. PubMed ID: 33256274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
    Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
    Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular immunotherapy for malignant gliomas.
    Lin Y; Okada H
    Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.